NEW YORK--(BUSINESS WIRE)--Saghmos Therapeutics, Inc., a privately held biopharmaceutical company whose mission is to prevent and treat kidney injury due to contrast dyes, today announced that it will present at the 25th BioCentury Future Leaders conference New York City.
Anna Kazanchyan, M.D., Chief Executive Officer and Chairwoman of Saghmos, will provide an overview of the company and its lead program, ST-62516, which is positioned to enter Phase 3 development to improve cardiorenal outcomes in patients undergoing percutaneous coronary intervention (PCI). The presentation is scheduled for Friday, March 23, 2018, at 2pm EDT in Room 402/403 at the Millennium Broadway Hotel & Conference Center in New York, NY.
About Saghmos Therapeutics
Saghmos Therapeutics is a
privately held biopharmaceutical company whose mission is to prevent and
treat kidney injury due to contrast dyes. Saghmos’ lead program,
ST-62516 is positioned to enter Phase 3 development for reduction of
major adverse renal and cardiac events (MARCE) associated with
contrast-induced acute kidney injury (CI-AKI) in patients undergoing
percutaneous coronary intervention (PCI). CI-AKI is a silent killer,
leading to heart attacks, prolonged hospitalization, need for dialysis
and death. It is a multi-billion dollar market opportunity, with no
FDA-approved drugs for prevention or treatment.